Have you ever wondered if AI could help doctors find cancer faster and more accurately? In this episode, we explore OmniScreen, an AI-powered biomarker tool that is revolutionizing cancer diagnostics.

Joe Oakley, a pathologist and expert in digital pathology, explains how OmniScreen was trained on 3 million digital slides to detect cancer biomarkers with higher precision and speed. He shares how AI is reducing testing time, preserving tissue samples, and improving early cancer detection.

We also tackle the big question: Will AI replace pathologists? Joe breaks down the role of AI in pathology and why it should be seen as a tool to assist rather than replace doctors. Plus, learn how AI is helping hospitals, pharmaceutical companies, and researchers in drug development and clinical trials.

🔹 Key Topics Covered:
✔️ How OmniScreen is transforming cancer diagnostics
✔️ AI vs. traditional cancer detection methods
✔️ The role of AI in hospitals, pharma, and research
✔️ Will AI replace pathologists? The expert’s take
✔️ The future of AI-driven cancer research

🎙️ Guest: Joe Oakley, Lead Consultant/ Founder at Oakley Pathology Consultants, LLC
🔗 Connect with Joe Oakley: LinkedIn 

📌 Chapters:
00:00 Introduction
00:49 The problem: Can AI find cancer faster?
01:19 How OmniScreen speeds up cancer detection
01:58 The AI behind OmniScreen: Trained on 3 million slides
02:28 How cancer diagnosis worked before AI
04:31 The evolution of pathology and diagnostic tools
06:10 Why AI can detect cancer better than traditional tests
07:24 How OmniScreen works step by step
08:34 The real impact: Saving time, tissue, and costs
10:04 Who are the early adopters of OmniScreen?
11:59 The role of hospitals, pharma, and researchers
14:12 The cost of AI-driven cancer detection
15:52 The big debate: Will AI replace pathologists?
17:10 Why AI is a tool, not a replacement
19:35 Future impact on drug development and clinical trials
22:09 AI’s role in personalized medicine
24:42 The future of AI in cancer research
27:10 How AI is changing clinical trials
30:05 Key takeaways from the episode
32:40 Where to find Joe Oakley & final thoughts
36:00 Closing remarks

Subscribe for more insights on AI and healthcare!

For transcripts, check out the podcast website - www.lifesciencespod.com

Have you ever wondered why marketing in the life sciences industry is so different from traditional marketing? In this episode, we dive deep into the power of science marketing, the impact of brand storytelling, and how companies can successfully position their products in a competitive market.

From publishing content to collaboration with industry, we'll show you how to harness the power of science marketing for success. Why do some breakthrough innovations never reach their full potential, while others become industry leaders?

Our guest, Elizabeth Chabe, is the CEO of High Touch Group and a leading expert in scientific marketing. She shares invaluable insights on how companies can build credibility, shorten sales cycles, and effectively communicate complex innovations to investors, researchers, and the public.

We also explore:
✅ Why scientific breakthroughs fail without proper marketing 
✅ The biggest mistakes life sciences companies make 
✅ How to pitch complex ideas to experts & decision-makers 
✅ The secret behind pharma ads & storytelling in healthcare 
✅ How conferences & live demonstrations can transform your brand 

This episode is packed with expert strategies, real-world examples, and game-changing marketing insights for biotech, medtech, and pharma professionals.


⏱️ Chapters:
00:00 Introduction
02:24 Why Science Marketing is Crucial
05:38 How to Tailor Your Message for Experts
14:29 The ROI of Marketing – Why It’s a Game Changer
22:24 The Secret Behind Pharma Ads & Storytelling
27:31 A Genius Conference Marketing Strategy
32:25 The Future of Science Marketing & Live Engagement
35:04 Why Elizabeth Runs a Global Business
38:50 A Sneak Peek Into Her Book – The Giants Ladder
42:31 Final Thoughts & Takeaways

🔗 Links Mentioned:
📌 Connect with Elizabeth Chabe on LinkedIn: https://www.linkedin.com/in/eviselli/
📌 Learn more about the work she does at High Touch Group
📌 Grab a copy of Elizabeth's book, The Giants Ladder

For transcripts, check out the podcast website - www.lifesciencespod.com

Have you ever wondered why so many new drugs fail even after years of research and billions in investment? In this episode, we dive deep into the challenges of drug commercialization, the role of AI in pharma, and the biggest mistakes companies make before going to market.

Our guest, Dan Cummings, is a leading expert in go-to-market strategy, having worked with top health tech, medtech, and biotech startups. He shares insider insights on why even successful clinical trials don’t guarantee a product’s success and how companies can improve their chances.

We also explore:
- The shocking statistics behind drug approvals 
- Why less than a third of new drugs in 2025 will meet expectations
- The #1 mistake pharma companies make before launch 
- How AI is transforming drug development & commercialization 
- What makes some drugs cost millions of dollars, while others are much cheaper 

This episode is packed with industry insights, expert opinions, and bold predictions about the future of pharmaceuticals.

Chapters:

• 00:00 Introduction
• 03:54 The Challenges of Drug Commercialization
• 05:35 Market Access & Value-Based Pricing
• 12:00 Predictions for 2025 Drug Approvals
• 13:23 The Role of AI in Pharma
• 16:59 Why Most Drug Launches Miss Expectations
• 18:25 Lessons from Biotech Success Stories
• 23:46 The Future of Pharma & Go-to-Market Strategies
• 29:31 How Companies Can Improve Their Launch Success
• 35:56 Final Thoughts & Takeaways

🔗 Links Mentioned:
📌 Connect with Dan Cummings on LinkedIn
📌 Learn more about Envision Pharma Group


If you enjoyed this, you'll like these other past episodes:
How to Combine Storytelling and Science for Impact
Understanding Drug Pricing and the Impact of the Inflation Reduction Act

For transcripts, check out the podcast website - www.lifesciencespod.com

Have you ever wondered why so many clinical trials fail before reaching the market? In this episode, we dive deep into the hidden challenges of clinical trials with Rob Freishtat, President and Co-Founder of Uncommon Cures and a professor at George Washington University School of Medicine and Health Sciences.

Rob shares insider knowledge on why over 55% of clinical trials fail, the high costs of drug development, and how misaligned priorities between researchers, regulators, and sponsors can derail promising treatments. He also reveals how streamlining clinical trials, improving patient recruitment, and leveraging AI and real-world data can help bring life-saving drugs to market faster.

If you're curious about the future of medicine, drug approvals, or how rare disease treatments are developed, this is an episode you don’t want to miss!

Chapters:

00:00 Introduction – Why Clinical Trials Matter
02:59 The Real Reason Many Clinical Trials Fail
08:18 Where the Industry Wastes the Most Money
15:28 How Misalignment in Drug Development Happens
27:00 The Future of AI in Clinical Trials
34:19 How to Fix Broken Clinical Trials
41:03 Final Thoughts & Key Takeaways

🔗 Links Mentioned:
🌐 Visit Uncommon Cures
📌 Follow Rob Freishtat on LinkedIn

More from Life Sciences 360:
🎥 Youtube:/ @lifesciences360

For transcripts, check out the podcast website - www.lifesciencespod.com

In this episode of Life Sciences 360, we dive deep into the world of GLP-1 medications with Dr. Jonathan Kaplan. We discuss weight management, how these medications work, their impact beyond weight loss, and the ethical considerations surrounding their use. Dr. Kaplan shares his insights on the healthcare industry's evolving landscape, the economic implications, and why these medications are changing everything from cosmetic surgery to chronic disease management.

Chapters:

00:00 Introduction  
00:02 Dr. Jonathan Kaplan’s Background  
00:16 Overview of GLP-1 Medications  
00:25 The Significance of GLP-1s  
00:35 Future FDA Approvals  
00:51 Welcome to the Episode  
01:12 Meet Dr. Jonathan Kaplan  
01:19 Dr. Kaplan’s Journey into Weight Management  
02:09 Early Days Before the GLP-1 Hype  
02:30 Compounding Pharmacy and Medication Shortages  
03:17 Success of the Weight Management Program  
03:23 YouTube Subscriber Request  
04:17 GLP-1 Mechanisms Explained  
05:00 How GLP-1s Work in the Body  
05:51 Historical Timeline of GLP-1 Medications  
06:48 Semaglutide’s Evolution  
07:23 The Rise of Ozempic and Wegovy  
07:43 New Developments in Weight Management  
08:54 Accidental Discoveries and Hormones  
09:35 Significance of GLP-1 Discoveries  
10:02 Medication Approval and Insurance Hurdles  
10:43 Patient Expectations vs. Reality  
12:09 Misconceptions About Weight Loss  
12:51 Other Health Benefits Beyond Weight Loss  
14:10 The Complex Psychology of Weight Loss  
15:16 Importance of Diet and Exercise  
16:10 How to Get Access to These Medications  
18:02 Transparent Pricing Model  
20:19 Maintenance and Subscription Options  
22:04 Challenges with Insurance  
23:21 Insurance Pitfalls and Complications  
24:42 Speed of Access and Medication Availability  
25:41 Ethical Considerations in Prescribing GLP-1s  
27:28 Balancing Ethics and Accessibility  
29:35 Broader Impact on Public Health and Economics  
30:35 Transforming Healthcare Through Weight Management  
32:12 Future of GLP-1 Medications  
33:58 Changing Consumer Preferences and Food Labels  
35:51 Reflections on Dr. Kaplan’s Career  
37:06 Closing Remarks  
39:11 Key Takeaway on Safe Access  
41:03 Conclusion and Gratitude  

🔗 Links Mentioned:

Dr. Jonathan Kaplan, Founder and CEO at Build My Health

Linkedin -  (https://www.linkedin.com/in/buildmybod/)
- Visit Dr. Jonathan Kaplan’s website: (https://www.drwell.com)
- Website : (https://www.buildmybod.com/author/kaplan/)

- Follow Dr. Well on TikTok and Instagram: (https://www.tiktok.com/@drwellrx)

- Contact Dr. Jonathan Kaplan: [email protected]

- Follow Life Sciences 360 on LinkedIn 
(https://www.linkedin.com/company/life-sciences-360)

---

 Subscribe to our podcast for more on life sciences: 
🍎Apple podcast: https://apple.co/3RXPoS1
🟩 Spotify podcast: https://spoti.fi/3EbDZbr


#GLP1 #WeightLoss #HealthCare #LifeSciences360 #DrJonathanKaplan #Ozempic #Wegovy #WeightManagement #HealthAndWellness #GLP1Medications #Type2Diabetes #ObesityTreatment #MedicalPodcast #HealthyLiving #Pharmaceuticals #Semaglutide #Medicine #SciencePodcast #MedicalResearch #PreventiveHealth

For transcripts, check out the podcast website - www.lifesciencespod.com

In this episode of LifeSciences 360, we dive into the fascinating world of cell and gene therapy manufacturing with Carlos Yuraszeck. With over 16 years of experience, Carlos shares his deep insights into the unique challenges, opportunities, and innovations in the field, offering a detailed look into what it takes to bring life-saving therapies to patients. We cover everything from the design of manufacturing facilities to the complexities of quality systems, patient-centric innovations, and the future of allogeneic therapies.

If you're interested in the life sciences, cell and gene therapy, or just curious about cutting-edge advancements in medicine, this episode is for you!

Chapters:

00:00 - Intro  
00:02 - Understanding Cell and Gene Therapy Facilities  
00:09 - Challenges in Cell Therapy Facility Design  
00:26 - Automation in Manufacturing  
00:42 - Balancing Quality, Cost, and Time  
00:53 - Patient-Centric Manufacturing  
01:21 - Guest Introduction: Carlos Yuraszeck  
02:06 - Carlos’s Journey in Cell and Gene Therapy  
03:21 - Unique Factors in Facility Design  
04:14 - Making Facilities Operational  
05:09 - Subscription Appeal  
06:13 - Autologous vs. Allogeneic Cell Therapies Explained  
08:13 - Adjusting Processes Based on Patient Variability  
09:37 - Stem Cell Derived Therapies  
10:39 - Biotech Companies: Autologous or Allogeneic?  
12:07 - Strategic Decisions in Facility Design  
14:50 - Phase-Appropriate Quality Systems  
16:45 - Regulatory Flexibility and Urgency for Patients  
18:08 - Change Control in Early vs. Late Phases  
19:02 - Batch Records and Operator Judgment  
20:27 - Training Focus for Different Phases  
22:38 - Balancing Regulatory Requirements and Innovation  
24:32 - Risk Assessment Based on Patient Needs  
26:18 - The Potential of CAR T Therapies  
28:05 - The Allogeneic Space and Future Prospects  
31:00 - The Transformative Impact of Cell Therapy  
32:22 - Carlos’s Career Lessons and Fear of the Unknown  
34:45 - Closing Remarks and Subscription Reminder  
36:37 - Outro

---

🔗 Links Mentioned:

Connect with Carlos on LinkedIn: 
https://www.linkedin.com/in/carlos-yuraszeck-5400091/


- Follow Life Sciences 360 on LinkedIn 
(https://www.linkedin.com/company/life-sciences-360)

---

 Subscribe to our podcast for more insights on life sciences: 
🍎Apple podcast: https://apple.co/3RXPoS1
🟩 Spotify podcast: https://spoti.fi/3EbDZbr

💬 Let us know in the comments: Did you know worms could be this powerful?  
👍 Don't forget to hit Like and Subscribe for more fascinating interviews with leaders in life sciences!


Make sure to subscribe for more industry insights, and don't forget to leave a comment or question for our guest, Carlos Yuraszeck!

---

#Celltherapy #GMPoperations #executivedirector #astellaspharma #CellTherapyManufacturing #facilitydesign #DesigningCell

For transcripts, check out the podcast website - www.lifesciencespod.com

In this episode of Life Sciences 360, we dive into the evolution of pharmaceutical and biotech manufacturing with our guest, Scott, a seasoned expert with nearly 30 years of experience working with industry giants like Novartis, Biogen, Thermo Fisher, and Merck. Scott shares insights on cell culture technology, mRNA vaccines, and the challenges and innovations in scaling biotech facilities. Discover the impact of collaboration and how organizations like the International Society for Pharmaceutical Engineering (ISPE) are transforming the landscape.


Chapters :
00:00 - Introduction to Vaccine Technologies
00:14 - Importance of Collaboration in Pharma Manufacturing
00:22 - The Role of Technology Ecosystems
00:30 - Scott’s Experience with ISPE
00:46 - Motivation Behind Pharma & Biotech Careers
01:09 - Welcoming Scott to Life Sciences 360
01:19 - Scott’s Background & Industry Experience
01:45 - Integrating Technology in Pharmaceutical Facilities
01:59 - Scott’s Current Role & Unique Challenges
02:18 - Interview Kickoff: Scott’s Career Insights
03:11 - The Evolution of Drug Manufacturing
03:39 - Insights for Non-Pharma Audiences
03:59 - Changes in Vaccine Manufacturing Over the Years
04:40 - mRNA Technology and Its Impact
05:05 - Encouraging Viewers to Subscribe
05:59 - Driving Innovation in Manufacturing Facilities
07:01 - Challenges in Scaling New Therapies
08:17 - Overcoming Challenges in New Tech Implementation
09:03 - The Role of Technology Vendors
10:08 - Advancements in Manufacturing Technology
11:02 - Evolution of Biotech Processes
12:09 - Consulting in Cell and Gene Therapy
13:02 - The Infancy of Cell and Gene Therapy
13:23 - Introduction to SoulVentum
14:01 - Separation from 3M and Vision for SoulVentum
15:01 - Scott’s Role at SoulVentum
15:33 - Scott’s Contributions to ISPE
17:18 - Identifying Award-Winning Facilities
18:39 - ISPE Facility of the Year Criteria
20:18 - Global Reach of ISPE Submissions
21:41 - Geographical Insights Post-Pandemic
22:47 - The Role of ISPE in Pharma Collaboration
23:31 - ISPE Communities of Practice
24:47 - Forums & Conferences by ISPE
26:19 - Local ISPE Chapters & Regional Support
26:58 - Scott’s Take on Industry Networking
28:05 - The Importance of Professional Networks
29:05 - Advice on Building a Career in Pharma
30:21 - Scott’s Mission in the Industry
31:42 - Personal Impact of the Work in Pharma
32:26 - Patient Stories and Their Motivational Impact
33:22 - Closing Thoughts & How to Connect with Scott

🔗 Links Mentioned:

Connect with Scott on LinkedIn: 
https://www.linkedin.com/in/scott-billman-a865093b/
Learn more about ISPE: 
https://ispe.org/


- Follow Life Sciences 360 on LinkedIn 
(https://www.linkedin.com/company/life-sciences-360)

---

 Subscribe to our podcast for more insights on life sciences: 
🍎Apple podcast: https://apple.co/3RXPoS1
🟩 Spotify podcast: https://spoti.fi/3EbDZbr

💬 Let us know in the comments: Did you know worms could be this powerful?  
👍 Don't forget to hit Like and Subscribe for more fascinating interviews with leaders in life sciences!


#LifeSciences360 #PharmaceuticalIndustry #Biotech #PharmaManufacturing #DrugDevelopment #mRNA #CellTherapy #GeneTherapy #ISPE #BiotechInnovation #PharmaceuticalEngineering #VaccineTechnology #PharmaCareers #PharmaInnovation #LifeSciences #SoulVentum #HealthcareManufacturing #BiotechIndustry #PharmaTechnology #Industry4

For transcripts, check out the podcast website - www.lifesciencespod.com

Welcome to another episode of Life Sciences 360! Today, we're diving into the intricate world of life sciences leadership with a special guest who's worn nearly every hat in the industry—Taggart McGurrin. Starting in finance, transitioning to law, and tackling leadership roles across strategy, operations, and regulatory affairs, Taggart McGurrin brings a unique perspective on how to navigate the high-stakes environment of life sciences.

In this episode, we cover:

The Complexities of Life Sciences: Taggart McGurrin explains why this industry has more risk areas than most, from regulatory hurdles to financial pressures.

Triple Threat in Leadership: Discover Taggart's approach to balancing “What you have, what you need, and what you want” for effective decision-making.

Navigating the CFO/COO Role: Taggart shares insights on managing dual executive roles, emphasizing the importance of detail, resilience, and creative pragmatism.

Overcoming Financial Hurdles: Insights on cash flow challenges and how proper planning and investor relations drive success.

Unique Challenges in Life Sciences: The balancing act between meeting regulatory demands and fostering innovation.

Whether you’re a leader in life sciences, considering a C-level role, or just curious about this industry, this episode is packed with practical insights!

Chapters: 
00:00 - Intro
01:00 - The Life Sciences Landscape
03:30 - Importance of Patient-Centric Leadership
10:00 - The Role of Detail in Executive Leadership
17:00 - Managing Financial Pressures in Life Sciences
22:00 - Navigating Regulatory Challenges
27:00 - Raising Capital in Life Sciences
29:00 - Final Takeaways

If you’re looking to understand the unique challenges and leadership dynamics within life sciences, this is a must-watch! Don’t forget to subscribe for more content on leadership, innovation, and life sciences trends. 💡

Connect with Tagg McGurrin: 
https://www.linkedin.com/in/taggartmcgurrin/

- Follow Life Sciences 360 on LinkedIn 
(https://www.linkedin.com/company/life-sciences-360)

---

 Subscribe to our podcast for more insights on life sciences: 
🍎Apple podcast: https://apple.co/3RXPoS1
🟩 Spotify podcast: https://spoti.fi/3EbDZbr

💬 Let us know in the comments: Did you know worms could be this powerful?  
👍 Don't forget to hit Like and Subscribe for more fascinating interviews with leaders in life sciences!

#LifeSciences360  #PharmaceuticalLeadership  #LifeSciencesIndustry  #HealthcareLeadership  #ExecutiveInsights  #PharmaInnovation  #LeadershipInLifeSciences  #FinanceInLifeSciences  
#RegulatoryChallenges  #LifeSciencesCareers  #CFOCOO #TripleThreatLeadership  #FDACompliance  #LifeSciencesPodcast  #PharmaRisks  
#PatientCentricLeadership  #CorporateStrategy #HealthcareInnovation  #BiotechLeadership  #InvestmentInPharma

For transcripts, check out the podcast website - www.lifesciencespod.com

In this episode of Life Sciences 360, host Harsh Thakkar sits down with Marc Sheetz, Associate Dean of Research at Midwestern University's College of Pharmacy, to discuss the growing concern of antimicrobial resistance and the field of pharmacometrics. 

Marc sheds light on how pharmacometrics is shaping the future of medicine by using predictive models to personalize dosing, making drug treatments more effective while reducing toxicity. This episode dives deep into the intersection of pharmacometrics, AI, and machine learning, revealing how the future of patient care and treatment is rapidly evolving. Marc also shares insights from his current research in the infectious disease space, including his work with pediatric ICU patients.

Chapters:

00:00 Introduction
00:03 Antibiotic Toxicity and Population Models
01:02 The Importance of Antibiotics and Public Health Challenges
01:22 Introduction to Pharmacometric Science
03:12 Using Data in Medicine for Future Predictions
06:01 Tailoring Drug Dosages for Individuals
09:36 The Global Variation in Drug Dosages and Challenges
14:44 The Future of Personalized Medicine and Precision Dosing
21:39 The Intersection of AI, Machine Learning, and Pharmacometrics
26:35 The Role of Technology in Medicine
30:01 How Dosing Software and AI Are Enhancing Patient Care
36:54 Innovation and Research Trends in Medicine


- Connect with Marc Sheetz on Twitter: 
(https://twitter.com/IDPharmacometrics)  

- Learn more about Midwestern University: 
(https://www.midwestern.edu)  

- Follow Life Sciences 360 on LinkedIn 
(https://www.linkedin.com/company/life-sciences-360)

---

 Subscribe to our podcast for more insights on life sciences: 
🍎Apple podcast: https://apple.co/3RXPoS1
🟩 Spotify podcast: https://spoti.fi/3EbDZbr

💬 Let us know in the comments: Did you know worms could be this powerful?  
👍 Don't forget to hit Like and Subscribe for more fascinating interviews with leaders in life sciences!


#Pharmacokinetics #Pharmacodynamics #AntibioticResistance, #AntimicrobialResistance #AIinHealthcare #PrecisionMedicine #PersonalizedMedicine #Infectious #DiseaseResearch

For transcripts, check out the podcast website - www.lifesciencespod.com

Imagine knowing how your body will respond to a medication before you even take it! In this episode, Harsh Thakkar interviews Sarah Rogers, co-founder and president of the American Society of Pharmacovigilance (ASP) and an Assistant Professor at Texas A&M. Together, they dive deep into the fascinating world of pharmacogenomics—how your genetic makeup affects your response to medications. They discuss the challenges of pharmacogenomic testing, real-world examples of adverse drug reactions, and the future of personalized medicine. 


Chapters:

00:00 - Intro
00:16 - Breaking Down Pharmacogenomics
01:39 - Guest Introduction: Sarah Rogers  
02:18 - Explaining Pharmacogenomics to a Child
03:24 - Sarah's Start in Pharmacogenomics  
04:54 - The Power of Pharmacogenomics
07:00 - Pharmacogenomics Clinic at Texas A&M  
09:02 - Challenges of Standardizing PGX Testing
11:14 - The Ideal Pharmacogenomics Workflow
13:39 - Real-World Example of PGX in Action
15:44 - Importance of Integrating PGX into EHR 
20:24 - AI and Digital Twins in Pharmacogenomics
21:52 - Lessons Learned in Pharmacogenomics
24:46 - Looking to the Future of Personalized Medicine
28:18 - Final Takeaway  
30:22 - Outro 


Connect with Sarah Rogers:
- LinkedIn: (https://www.linkedin.com/company/american-society-of-pharmacovigilance)  
- STRIPE Initiative LinkedIn: (https://www.linkedin.com/company/stripe-pharmacogenomics)  
- Twitter: (https://twitter.com/amsocietypharm)  
- Newsletter signup for the American Society of Pharmacovigilance:  https://www.stopadr.org/

Here are links for some of the information that I mentioned during our meeting:
- STRIPE Annual Meeting and Consensus Workshop - (https://www.usp.org/node/289416)
 - Collaborative Communities: Addressing Health Care Challenges Together
(https://www.fda.gov/about-fda/cdrh-strategic-priorities-and-updates/collaborative-communities-addressing-health-care-challenges-together)
- Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community - (https://stopadr.org/stripe)
- Texas A&M Interprofessional Pharmacogenomics (IPGx) Clinic - (https://ibt.tamu.edu/cores/Texas%20ClinicoGenomics/Texas%20ClinicoGenomics.html)
- National Action Plan for Adverse Drug Event Prevention - (https://health.gov/sites/default/files/2019-09/ADE-Action-Plan-508c.pdf)
- Figure showing Stakeholders Involved in the Lifecycle of a Pharmacogenomics Test
(https://www.nature.com/articles/s41397-024-00345-y/figures/1)


- Subscribe to our podcast for more insights on life sciences: 
🍎Apple podcast: https://apple.co/3RXPoS1
🟩 Spotify podcast: https://spoti.fi/3EbDZbr

💬 Let us know in the comments: Did you know worms could be this powerful?  
👍 Don't forget to hit Like and Subscribe for more fascinating interviews with leaders in life sciences!

---
 
#Pharmacogenomics #PersonalizedMedicine #SarahRogers  #PGX #GeneticMakeup

For transcripts, check out the podcast website - www.lifesciencespod.com